| answer text |
<p>NHS England is committed to improving diagnosis rates, and recovering to the national
ambition for two thirds of people with dementia to have a formal diagnosis. This commitment
is included in the operational planning guidance for 2023/24, giving clear direction
for integrated care boards to prioritise dementia. The national ambition includes
provision for a sub-type diagnosis.</p><p>NHS England has established a dedicated
national programme team which co-ordinates the preparations for the potential roll
out of new treatments, for use in the earlier stages of Alzheimer’s disease. These
plans assume that, if these new treatments are approved by the regulators, significant
additional diagnostic capacity including amyloid positron emission tomography and
computed tomography (PET-CT) lumbar puncture and magnetic resonance imaging (MRI),
will be needed both to identify patients who are most able to benefit, and to provide
important safety monitoring for potential adverse effects during treatment.</p><p>The
team at NHS England is taking concrete steps to ramp up preparations across the country
and assess the additional scanning, treating, and monitoring capacity that will be
needed. This encompasses securing additional diagnostic capacity including MRI, lumbar
puncture, and PET-CT.</p>
|
|
